Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
AB Science today reports its revenues for the first half of 2025 and provides an…
PRESS RELEASEAB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared to the first half of 2024, amounting to €2.7 million as of June 30, 2025Capital increase through private placements for a total amount of €6.3 million Clinical development Masitinib platform: Authorization from several European countries for the confirmatory Phase 3 study...
Nasdaq GlobeNewswire
10/10/2025
Press release: Transparency Notification from Shareholder
Transparency Notification from ShareholderGhent, Belgium – 10 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below…
Nasdaq GlobeNewswire
10/10/2025
Single-use Bioprocessing Market worth US$33.67 billion by 2030 with 13.3% CAGR |…
Browse in-depth TOC on "Single Use Bioprocessing Market" Browse in-depth TOC on "Single Use Bioprocessing Market" 740 - Tables 65 - Figures 570 - Pages Based on region, the single-use bioprocessing market is segmented into six major regions, namelyNorth America,Europe,Asia Pacific,Latin America, theMiddle East, andAfrica. In 2024,North Americadominated the single-use bioprocessing market. Significant spending on pharmaceutical R&D activities,...
PR Newswire
10/10/2025
Global Healthcare and Wellness Market Outlook 2024-2030: CAM, Beauty Care, and…
The global market for Healthcare and Wellness was estimated to be worth USD 5243 Million in 2023 and is forecast to a readjusted size of USD 8419.1 Million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030. The global market for Healthcare and Wellness was estimated to be worthUSD 5243 Millionin 2023 and is forecast to a readjusted size ofUSD 8419.1 Millionby 2030 with a CAGR of 7.0% during the forecast period 2024-2030. Download Free Data What are the key...
PR Newswire
10/10/2025
Global Cigar Humidors Market to Reach $628 Million by 2031, Driven by Luxury and…
The global market for Cigar Humidors was valued at USD 370 Million in the year 2024 and is projected to reach a revised size of USD 628 Million by 2031, growing at a CAGR of 8.0% during the forecast period. The global market for Cigar Humidors was valued atUSD 370 Millionin the year 2024 and is projected to reach a revised size ofUSD 628 Millionby 2031, growing at a CAGR of 8.0% during the forecast period. Download Free Data What are the key factors driving the growth of...
PR Newswire
10/10/2025
Management Rotation at Three MAXIMA GRUPĖ Companies
Management Rotation at Three MAXIMA GRUPĖ CompaniesMAXIMA GRUPĖ announces that, as of 13 October 2025, Jolanta Bivainytė is appointed as CEO of MAXIMA GRUPĖ, Kristupas Buzys – as CEO of MAXIMA LT, UAB and Tomas Bazys – as CEO of FRANMAX, UAB. Jolanta Bivainytė will take over as Chairwoman of the Board and CEO of MAXIMA GRUPĖ on October 13, replacing Manfredas Dargužis. M. Dargužis is appointed as the Head of Expansion of “Vilniaus prekyba“ and will continue to serve as a member of the...
Nasdaq GlobeNewswire
10/10/2025
MAXIMA GRUPĖ Borrows EUR 260 Million from SEB and ING Banks to Redeem Bonds
MAXIMA GRUPĖ Borrows EUR 260 Million from SEB and ING Banks to Redeem BondsMAXIMA GRUPĖ, UAB (hereinafter – MAXIMA GRUPĖ) announces that it has signed a short-term 2-year financing agreement for a total amount of EUR 260 million with Skandinaviska Enskilda Banken AB, AB SEB bankas (together EUR 130 million) and ING Belgium SA/NV (EUR 130 million). The funds received from the banks will be used for the early redemption of the MAXIMA GRUPĖ issued long-term bonds and for its related...
Nasdaq GlobeNewswire
10/10/2025
NOTICE OF EXERCISE OF MAKE WHOLE CALL OPTION
NOTICE OF EXERCISE OF MAKE WHOLE CALL OPTIONMAXIMA GRUPE, UAB (the "Issuer")1€240,000,000 6.250 per cent. Notes due 2027 (the "Notes")(ISIN: XS2485155464) (Common Code: 248515546) 10 October 2025We refer to the terms and conditions of the Notes (the " Conditions "). Capitalised terms used in this notice that are not otherwise defined have the meaning given to them in the Conditions.Pursuant to Condition 6(e) ( Redemption at the Option of the Issuer (Make Whole) )…
Nasdaq GlobeNewswire
10/10/2025
Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300…
Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has purchased an additional $500,000 worth of Ethereum (ETH), bringing its total investment in ETH to $1.5 million.This acquisition was executed pursuant to Cosmos Health’s previously announced $300 million digital assets facility, which is part of the Company’s broader strategic initiative to diversify its balance sheet and...
Nasdaq GlobeNewswire
10/10/2025
Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in…
Under the agreement, Renellence will distribute the MDR-approved (Medical Device Regulation) hyaluronic acid filler range Croma saypha® in Canada, further expanding access to Croma's science-driven, high-quality aesthetic solutions. The partnership reflects a shared commitment to innovation, excellence, and customer-focused service, laying the foundation for sustainable long-term growth. Under the agreement, Renellence will distribute the MDR-approved (Medical Device Regulation) hyaluronic…
PR Newswire
10/10/2025
NTG Nordic Transport Group A/S - Q3 2025 Conference Call
NTG Nordic Transport Group A/S – Q3 2025 Conference Call We expect to release the Q3 2025 interim results of NTG Nordic Transport Group on the evening of November 10, 2025. A webcast and conference call will be held in the morning of November 11, 2025, at 10:00 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Christian D. Jakobsen will present the Q3 2025 Interim Financial Report. The presentation will be followed by a Q&A session.Date:November 11, 2025Time:...
Nasdaq GlobeNewswire
10/10/2025
Berlin Heals Holding AG Successfully Completes Enrollment in Phase I of the…
"Completing enrollment in under 6 months since implanting our first patient marks a pivotal moment for the company and reflects the degree of unmet need we are hearing from people living with Heart Failure," said Berlin Heals Holding Chief Executive OfficerJohn Brumfield. "We are very grateful to the patients, their families and the trial investigators for their enthusiasm and look forward to sharing topline results from the Phase I study next year." "Based on results…
PR Newswire
10/10/2025
SKF to publish Q3 report on 29 October
To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers:Link to web event: https://www.investis-live.com/skf/68c40e612728d2001df6538b/jnxer Sweden: +46 8 5051 0031 UK / International: +44 207 107 0613 To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers: Link to web event:https://www.investis-live.com/skf/68c40e612728d2001df6538b/jnxer Sweden : +46 8 5051 0031UK /…
PR Newswire
10/10/2025
Idorsia successfully completes an upsized offering of shares – funding the…
Ad hoc announcement pursuant to Art. 53 LR Idorsia successfully completes the offering of 16.4 million new and treasury shares – upsized from 15 million shares – through an accelerated bookbuilding process with gross proceeds of CHF 65.6 million Allschwil, Switzerland – October 10, 2025Idorsia Ltd (SIX: IDIA, “Idorsia”) announces that it has successfully raised CHF 65.6 million through the placement of 16.4 million registered shares (the “Offer Shares”) at a placement price of CHF 4...
Nasdaq GlobeNewswire
10/10/2025
NeuroVigil’s iBrain™ in TIME’s “Best Inventions of 2025”
SAN FRANCISCO and WATERLOO, Ontario and MONTREAL and LEIPZIG, Germany, Oct.09, 2025(GLOBE NEWSWIRE) -- TIME has announced today that Silicon Valley-based Neurotechnology Powerhouse NeuroVigil’s iBrain™ had been selected by its editors as one ofThe Best Inventions of 2025.The new ultra-small device, the size of two quarters, has twice the battery life of the previous design, four times more channels, and has sixteen different endpoints, enabling the AI-based hunt for biomarkers related...
Nasdaq GlobeNewswire
10/10/2025
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with…
Platinum-Resistant Ovarian Cancer Market Summary Platinum-Resistant Ovarian Cancer Market Summary Discover the platinum-resistant ovarian cancer new treatment @New Treatments for Platinum-Resistant Ovarian Cancer Key Factors Driving the Growth of the Platinum-Resistant Ovarian Cancer Market Rising Ovarian Cancer Incidence In 2024, in the 7MM, there were around 61K incident cases of ovarian cancer. Ovarian cancer cases are increasing, and long-term projections show...
PR Newswire
09/10/2025
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in…
Built on Alamar's proprietary NULISA™ platform, the NULISAqpcr BD-pTau217 Assay delivers unprecedented sensitivity and specificity from non-invasive sample types such as plasma, serum and dried blood spots. The research assay's direct measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials. Built on Alamar's proprietary NULISA™...
PR Newswire
09/10/2025
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology…
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history –– Improvements in overall clinical status at 3 years in the open-label extension studie sreported by clinicians and caregivers in 95% of patients treated with zorevunersen – CAMBRIDGE, Mass. and BEDFORD, Mass., Oct.09, 2025(GLOBE NEWSWIRE) --Biogen Inc...
Nasdaq GlobeNewswire
09/10/2025
Endo Announces Nine New and Modified Presentations at the Sexual Medicine…
The nine new and modified Endo-sponsored and Endo-supported presentations are below: The nine new and modified Endo-sponsored and Endo-supported presentations are below: Sponsored by Endo: Investigator-Initiated Research: About Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy. 1 It is estimated that PD can affect as many as 1...
PR Newswire
09/10/2025
Procedure of the Annual General Meeting
ANNOUNCEMENT NO. 2949 October 2025Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter.At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2024/25 was approved, and the Board of Directors and the Executive Board were granted discharge.The Annual General Meeting approved the...
Nasdaq GlobeNewswire
09/10/2025
Atelier Expressions announces the acquisition of French porcelain manufacturer…
'I have always admired JL Coquet's creations, which reflect a timeless heritage and impeccable craftsmanship,' says Tara S. Venu, Executive Director of Atelier Expressions. "We are excited about the opportunities offered by this acquisition. The spirit of JL Coquet is perfectly in line with our ambition to bring international recognition to companies that embody exceptional quality and craftsmanship." 'I have always admired JL Coquet's creations, which reflect a timeless heritage…
PR Newswire
09/10/2025
XRlabs SIM Named to TIME Best Inventions 2025
"This recognition by TIME is a validation of our core mission: to redefine the surgical standards of care," said Dr. Ali Haddad, Founder and CEO of XRlabs and practicing neurosurgeon. "As a surgeon-founder, I built XRlabs SIM, our first product, to solve a fundamental unmet need: the lack of intuitive, integrated deep vision that prevents surgical knowledge from scaling globally. XRlabs SIM delivers a new layer of precision and confidence to surgeons, accelerating the…
PR Newswire
09/10/2025
Oxurion provides an update related to its investment strategy in digital assets
Leuven, BELGIUM, October 9, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR) announces today that the completion of the new financing aimed at investing in digital assets (Bitcoin and Ethereum), originally scheduled to close on September 25, 2025, is still in progress. Administrative and compliance-related procedures (notably KYC/AML checks)…
Actusnews Wire
09/10/2025
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…
Disclosure of Share Capital and Voting Rights Outstandingas of September 30, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (October 9, 2025 - 6:00 pm)– As of September 30, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...
Nasdaq GlobeNewswire
09/10/2025
Altri Comunicati
